Researchers from Biorchestra Ltd. presented preclinical data for BMD-001, a novel nanoparticle-formulated antisense oligonucleotide (ASO) being developed for the treatment of Parkinson’s disease (PD). miR-485-3p has been previously identified as a pathway and therapeutic target in neuroinflammatory disease, and the potential relevance of this target in PD was further confirmed through RNA-Seq and analysis of expression levels in animal models and patients with PD.